Carlos Doti: AstraZeneca’s Expanding Impact in Blood Cancer Care
Carlos Doti, VP US Medical Affairs of Oncology at AstraZeneca, shared a post on LinkedIn:
“ASH25 showcased AstraZeneca’s continued growth in hematology.
A decade ago, we presented one abstract. In 2025, we presented 65 abstracts, including:
- 15 oral presentations
- spanning 8 medicines
- 11 diseases
What makes this milestone meaningful isn’t just the science, but how our focus has evolved.
Our responsibility is clear: to help patients have the best quality of life.
As I hear directly from patients, what they want most is freedom from continuous treatment and the chance to return to what truly matters.
Thank you to Mary Caffrey for the opportunity to share these insights and discuss how AstraZeneca is advancing the future of blood cancer care. I encourage you to read the full piece in AJMC – The American Journal of Managed Care.”
Stay updated on all scientific advances with Hemostasis Today.
-
May 23, 2026, 03:47Satyam Arora: Welcoming the New ISBT Board for the 2026 Term
-
May 23, 2026, 03:33Brig Tathagata Chatterjee: Connecting With World Leaders in Hematology at ISH Congress
-
May 23, 2026, 03:18Mathangi Kumar: Dental Management Strategies for Congenital Hemophilia
-
May 23, 2026, 03:02Maitri Vaishnav: Anatomical Variability and Surgical Relevance of Corona Mortis
-
May 23, 2026, 02:26Muhammad Hashim: When the Blood Smear Told a Different Story Behind a ‘Critical’ Platelet Count
-
May 23, 2026, 02:20Augustina Isioma Ikusemoro: Understanding One of the Most Common and Preventable Transfusion Reactions
-
May 23, 2026, 02:15What’s Your Advice for the Newly Diagnosed? – ITP Support Association
-
May 23, 2026, 02:08Rob Maloney: When You Stop Building Only a Career and Start Building a Life of Significance
-
May 23, 2026, 02:04Rahmathullah S.N.: Key Takeaways on Successful Surgical Outcomes in Patients with Congenital Bleeding Disorders